Boehringer Ingelheim and partners start clinical development of a first-in-class, inhaled ...
Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC) 1 and OXB, 1 today announce the start of LENTICLAIR TM 1, a Phase I/II trial of BI 3720931, a novel, first-in-class, ...
Scientific Research Publishing11 小时
BDNF Gene Therapy: A Potential Solution for Neurodegenerative Diseases ()
A Potential Solution for Neurodegenerative Diseases. Open Access Library Journal, 12, 1-16. doi: 10.4236/oalib.1112714 . Alzheimer’s Disease (AD), a complex neurodegenerative condition, significantly ...